Filing Details

Accession Number:
0001209191-20-026615
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-01 18:00:12
Reporting Period:
2020-04-29
Accepted Time:
2020-05-01 18:00:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1772518 Elena Ridloff C/o Acadia Pharmaceuticals Inc.
3611 Valley Centre Drive, Suite 300
San Diego CA 92130
Evp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-04-29 10,000 $25.12 10,000 No 4 M Direct
Common Stock Disposition 2020-04-29 10,000 $50.74 0 No 4 S Direct
Common Stock Acquisiton 2020-04-29 3,245 $0.00 3,245 No 4 M Direct
Common Stock Disposition 2020-04-30 1,050 $49.22 2,195 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-04-29 10,000 $0.00 10,000 $25.12
Common Stock Restricted Stock Units Disposition 2020-04-29 3,245 $0.00 3,245 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,547 2029-04-29 No 4 M Direct
9,736 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
  4. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
  5. 25% of the 45,547 shares originally subject to the stock option vested and became exercisable on April 29, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
  6. The restricted stock units vest in four equal annual installments beginning 4/29/2020.